{
    "ticker": "GILD",
    "name": "Gilead Sciences, Inc.",
    "description": "Gilead Sciences, Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines in areas of unmet medical need. Established in 1987 and headquartered in Foster City, California, Gilead has made significant contributions to the treatment of various diseases, particularly in the fields of antiviral therapies, oncology, and inflammatory diseases. The company is best known for its groundbreaking HIV therapies, including Truvada and Biktarvy, which have transformed the landscape of HIV treatment. In addition to its HIV portfolio, Gilead has developed therapies for hepatitis C, such as Harvoni and Sovaldi, and has expanded its research into other serious conditions like cancer and autoimmune diseases. With a commitment to improving patient outcomes and advancing public health, Gilead invests heavily in research and development, collaborating with academic institutions and other biotechnology firms. The company\u2019s mission is to create a healthier world by providing access to life-saving medications and addressing global health challenges.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Foster City, California, USA",
    "founded": "1987",
    "website": "https://www.gilead.com",
    "ceo": "Daniel O'Day",
    "social_media": {
        "twitter": "https://twitter.com/gileadsciences",
        "linkedin": "https://www.linkedin.com/company/gilead-sciences/"
    },
    "investor_relations": "https://investors.gilead.com",
    "key_executives": [
        {
            "name": "Daniel O'Day",
            "position": "CEO"
        },
        {
            "name": "M. Michelle Berrey",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Antiviral Therapies",
            "products": [
                "Truvada",
                "Biktarvy",
                "Harvoni",
                "Sovaldi"
            ]
        },
        {
            "category": "Oncology",
            "products": [
                "Yescarta",
                "Zydelig"
            ]
        },
        {
            "category": "Inflammatory Diseases",
            "products": [
                "Filgotinib"
            ]
        }
    ],
    "seo": {
        "meta_title": "Gilead Sciences, Inc. | Innovative Biopharmaceuticals",
        "meta_description": "Explore Gilead Sciences, Inc., a leading biopharmaceutical company focused on innovative therapies for HIV, hepatitis, cancer, and more. Discover their pioneering approach to healthcare.",
        "keywords": [
            "Gilead Sciences",
            "Biopharmaceuticals",
            "HIV Treatment",
            "Hepatitis C",
            "Oncology",
            "Innovative Medicines"
        ]
    },
    "faq": [
        {
            "question": "What does Gilead Sciences specialize in?",
            "answer": "Gilead Sciences specializes in antiviral therapies, oncology, and inflammatory diseases."
        },
        {
            "question": "Who is the CEO of Gilead Sciences?",
            "answer": "Daniel O'Day is the CEO of Gilead Sciences, Inc."
        },
        {
            "question": "Where is Gilead Sciences headquartered?",
            "answer": "Gilead Sciences is headquartered in Foster City, California, USA."
        },
        {
            "question": "What are some of Gilead Sciences' main products?",
            "answer": "Gilead's main products include Truvada, Biktarvy, Harvoni, and Yescarta."
        },
        {
            "question": "When was Gilead Sciences founded?",
            "answer": "Gilead Sciences was founded in 1987."
        }
    ],
    "competitors": [
        "ABBV",
        "VRTX",
        "AMGN",
        "BMY"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRK",
        "REGN"
    ]
}